Skip to main content
Premium Trial:

Request an Annual Quote

Fisher Posts Double-Digit Increase in Q3 Revenues, Profit as it Awaits Thermo Merger

NEW YORK (GenomeWeb News) - Fisher Scientific yesterday reported a 10.8 percent increase in third-quarter sales and a 62 percent spike in income.
For the quarter ended Sept. 30, Fisher posted net sales of $1.51 billion as compared to $1.36 billion for the same quarter in 2005.
Net income increased to $152 million from $93.5 million last year.
Sales of scientific products and services in the third quarter increased to $1.17 billion, a 9.9 percent increase over the prior-year period, Fisher said.
As of Sept. 30, Fisher held $279 million in cash and equivalents.
Fisher is awaiting approval from the European Commission, which it expects by Nov. 9, to finalize its merger with Thermo Electron.
For 2006, Fisher said it expects total sales growth, excluding the effects of foreign exchange, of approximately 10 percent, with organic growth in its core scientific research and healthcare markets of 8 percent.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.